Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Jun, the oncoprotein.

P K Vogt1

  • 1Department of Molecular and Experimental Medicine, The Scripps Reasearch Institute, 10550 North Torrey Pines Drive, La Jolla, California, CA 9203, USA.

Oncogene
|June 13, 2001
PubMed
Summary
This summary is machine-generated.

Cellular Jun (c-Jun) and viral Jun (v-Jun) proteins can cause cancer. While c-Jun needs Jun N-terminal kinase (JNK) signaling, v-Jun is constitutively active, highlighting distinct oncogenic mechanisms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Class I PI3K in oncogenic cellular transformation.

Oncogene·2008
Same author

Constitutively active Rheb induces oncogenic transformation.

Oncogene·2008
Same author

Oncogenic signaling of class I PI3K isoforms.

Oncogene·2007
Same author

Phosphorylation by Akt disables the anti-oncogenic activity of YB-1.

Oncogene·2007
Same author

A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth.

Oncogene·2007
Same author

Retroviral oncogenes and TOR.

Current topics in microbiology and immunology·2003
Same journal

Aberrant splicing in human cancer shows possible functional impact on transcription factors.

Oncogene·2026
Same journal

The crosstalk between RNA m6A modification and protein lactylation: emerging insights into tumor progression.

Oncogene·2026
Same journal

Correction: Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway.

Oncogene·2026
Same journal

Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer.

Oncogene·2026
Same journal

Histone lactylation-driven IGF2BP3 promotes intrahepatic cholangiocarcinoma progression via SPP1/CD44-dependent macrophage polarization.

Oncogene·2026
Same journal

Correction: SIRT7 activates p53 by enhancing PCAF-mediated MDM2 degradation to arrest the cell cycle.

Oncogene·2026
See all related articles

Area of Science:

  • Oncogenic transformation
  • Molecular biology
  • Gene regulation

Background:

  • Cellular Jun (c-Jun) and viral Jun (v-Jun) are implicated in oncogenic transformation.
  • c-Jun requires Jun N-terminal kinase (JNK) signaling for its activity.
  • v-Jun is autonomous and constitutively active, independent of JNK.

Purpose of the Study:

  • To investigate the distinct and overlapping gene targets of c-Jun and v-Jun.
  • To determine the essential genes for oncogenic transformation within the Jun target spectra.
  • To advance the identification of transformation-relevant Jun targets using new technologies.

Main Methods:

  • Application of DNA microarrays technology to analyze gene expression.
  • Utilizing genetic screens to identify key genes.

Related Experiment Videos

  • Performing functional tests to validate gene roles in oncogenesis.

    • Main Results:

    • v-Jun and c-Jun regulate overlapping but not identical sets of genes.
    • The complete set of transformation-essential genes may not be fully contained within the intersection of their targets.
    • New technologies are enabling a deeper search for Jun's oncogenic targets.

    Conclusions:

    • Understanding the differential gene regulation by c-Jun and v-Jun is crucial for comprehending oncogenic transformation.
    • Further research combining high-throughput methods and functional validation is necessary to identify all critical genes driving the oncogenic phenotype.
    • The distinct mechanisms of Jun proteins offer potential avenues for targeted cancer therapies.